2027 年抗酸药市场报告(按细分市场、地域、动态、最新发展和战略见解)

  • Report Code : TIPRE00016359
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 182
Buy Now

Antacid Market Size, Share and Growth Analysis by 2027

Buy Now

 

2019 年全球抗酸药市场价值为 85.4797 亿美元,预计到 2027 年将达到 116.6683 亿美元,在 2020-2027 年期间以创纪录的 4.0% 的年增长率扩张。

抗酸药属于中和胃酸的药物类。它能有效治疗胃灼热、消化不良、胃酸过多和胃部不适。抗酸药有片剂、胶囊、液体和口服粉末等形式。氢氧化铝、碳酸镁、三硅酸镁、氢氧化镁、碳酸钙和碳酸氢钠是主要的抗酸药。抗酸药的成分有助于控制胃酸的 pH 值。

抗酸药通过医院、零售和网上药店等渠道销售。它们实际上是非处方药(OTC),也称为非处方药,只要按照标签上的说明或按照相关医疗保健专业人员的指示服用,就可以安全有效地服用。

 

抗酸市场 - COVID-19 的影响和分析

 

抗酸药需求持续增长,因为酸性是新冠肺炎药物的副作用之一

由于 COVID-19 全球大流行,抗酸药等基本非处方药 (OTC) 的销售受到影响。制药公司转向非实体营销活动并转向在线销售流程。为防止抗酸药等非处方药缺货,美国颁布了《冠状病毒援助救济和经济安全法案》(CARES),这是一项具有里程碑意义的立法,为受疫情影响的工人、医护人员和小型企业提供经济救济。疫情期间,欧洲对非处方药的需求激增。一些国家限制非处方药的销售和购买,以维持供应并抵消囤积或恐慌性购买。

在疫情期间,亚太抗酸药市场呈现出略有不同且积极的局面。印度是最大的制药中心之一,在制造商满负荷运营的情况下,占据了全球仿制药和品牌药的大部分份额。由于患者意识增强,亚太地区在 COVID-19 疫情期间实行自我药疗。酸度是 COVID-19 药物的常见副作用,这刺激了对抗酸药的需求。全球贸易中断和进口减少导致医疗用品短缺,从而导致中东、南美洲和中美洲价格上涨。无论价格和供应模式如何,在 COVID-19 疫情期间,全球对抗酸药的总体需求都得到了提升。

 

抗酸药市场未来趋势

多家抗酸药制造商致力于开发和推出新产品,以扩大其地理覆盖范围和产能,满足庞大的消费者群体。全球领先的消费者保健公司葛兰素史克消费者保健公司推出了 ENO Cooling,这是一款可立即缓解酸度并带来即时清凉感的产品。2017 年 5 月,总部位于孟买的 Piramal Enterprises 推出了一种名为 Polycrol 的槟榔味抗酸药,它不仅可以缓解酸度,而且还具有宜人的口感。2020 年 10 月,印度跨国制药公司 Dr. Reddy's Laboratories 在美国市场推出了非处方仿制药法莫替丁片,用于治疗胃食管反流病。此外,太阳制药有限公司推出了其首款消费者保健产品 Pepmelt,这是一种口溶颗粒状药物。

 

定制研究以满足您的需求

我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。

抗酸市场:

Antacid Market: Strategic Insights

Antacid Market
  • CAGR
    CAGR (2019 - 2027)
    4.0%
  • Market Size 2019
    US$ 8.55 Billion
  • Market Size 2027
    US$ 11.67 Billion

Market Dynamics

GROWTH DRIVERS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
FUTURE TRENDS
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX
OPPORTUNITIES
  • XXXXXXX
  • XXXXXXX
  • XXXXXXX

Key Players

  • Bayer AG
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Dr Reddys Laboratories
  • Pfizer Inc
  • Reckitt Benckiser Group Plc

Regional Overview

Regional And Country Scope
  • 北美(美国、加拿大、墨西哥)
  • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
  • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
  • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
  • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)

Market Segmentation

Segment 1剂型(片剂、液体、其他)
    Segment2药物类别(质子泵抑制剂、H2 拮抗剂、酸中和剂)
      Segment3分销渠道(医院药房、零售药房、网上药房)
        Segment4地理(北美洲、欧洲、亚太地区、中东和非洲、南美洲和中美洲)

          抗酸市场
          • Antacid Market
            复合年增长率(2019 - 2027 年)
            4.0%
          • 2019 年市场规模
            85.5 亿美元
          • 2027 年市场规模
            116.7 亿美元

          市场动态

          增长动力
          • 財政部
          • 財政部
          • 財政部
          未来的趋势
          • 財政部
          • 財政部
          • 財政部
          机会
          • 財政部
          • 財政部
          • 財政部

          关键人物;主力;重要一员

          •  
          • 拜耳公司
          • 葛兰素史克公司
          • 武田药品工业株式会社
          • 太阳制药工业有限公司
          • 赛诺菲
          • 勃林格殷格翰国际有限公司
          • 雷迪博士实验室
          • 辉瑞公司
          • 利洁时集团

          区域概况

          Antacid Market
          • 北美
          • 欧洲
          • 亚太
          • 南美洲和中美洲
          • 中东和非洲

          市场细分

          Antacid Market剂型
          • 药片
          • 液体
          • 其他的
          Antacid Market药物类别
          • 质子泵抑制剂
          • H2 拮抗剂
          • 酸中和剂
          Antacid Market分销渠道
          • 医院药房
          • 零售药店
          • 网上药店
          Antacid Market地理
          • 北美
          • 欧洲
          • 亚太地区
          • 中东和非洲
          • 南美洲和中美洲
          • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

           

          抗酸药市场驱动因素

           

          胃食管反流病 (GERD) 患病率不断上升

          胃食管反流病是一种消化系统疾病,会影响食管和胃之间的肌肉环。根据 2014 年发表的《GERD 流行病学最新进展:系统评价》报告的统计,该病的患病率为北美 18.1–27.8%、东亚 2.5–7.8% 和欧洲 8.8–25.9%。此外,2015 年进行的国家胃肠道调查显示,在接受检测的 71,000 人中,18% 的患者每周发作 2 次 GERD,31% 的患者每周至少发作一次 GERD。此外,调查还发现该病在女性中更为常见。近 35% 的 GERD 患者使用药物,而 55% 的患者首选质子泵抑制剂作为药物治疗。

           

          肥胖病例增加

          肥胖是引发 GERD 的主要危险因素。腹部脂肪过多会对胃造成压力,而食管裂孔疝会导致胃酸反流。此外,肥胖人群下食管括约肌 (LES) 松弛度增加会导致胃酸反流增多。大多数超重或 BMI 较高(25-30 千克/平方米)的人都患有胃酸过多或 GERD。根据世界卫生组织的数据,2016 年有超过 19 亿成年人超重,其中约 6.5 亿人肥胖。2017-2018 年,美国的肥胖患病率为 42.4%。肥胖一直是中国的主要健康问题,2004 年至 2014 年间,肥胖病例增加了三倍多。除了 GERD 之外,肥胖体质还会导致许多其他需要使用抗酸药等非处方药治疗的疾病,因此有利于全球抗酸药市场的增长。

           

          抗酸药市场限制

           

          低收入经济体缺乏与胃肠道疾病相关的认知

          由于行为和社会心理方面的原因,大多数人不愿在早期报告疾病。此外,对筛查方法的认识和采用程度较低往往会偏离治疗,从而危及健康程度。尽管取得了重大进展,但许多胃肠道疾病仍然没有得到很好的解释,需要安全、新颖和有效的治疗方法。由于环境因素的变化、饮食习惯和抗生素的过度使用,这些疾病在发展中经济体中更为普遍。在低收入国家,GERD、溃疡性结肠炎和克罗恩病等常见胃肠道疾病仍然需要最佳筛查和诊断。多种消化系统疾病需要广泛而昂贵的诊断测试,例如内窥镜检查、超声检查、CAT 扫描或 MRI。然而,基础设施的缺乏和缺乏熟练的专业人员阻碍了消化系统疾病的筛查。

           

          抗酸药市场按剂型细分

           

          易于储存,剂量适宜,可提高节段控制率

          根据剂型,全球抗酸药市场分为片剂、液体和其他类型。其中,片剂在 2019 年占据了市场主导地位,其次是液体,占据第二大市场份额,但在预测期内以最高的复合年增长率增长。市场上有各种类型的抗酸药片,包括可咀嚼的软糖、普通片剂和水溶性片剂。与其他形式相比,这些片剂易于储存,可提供足够的剂量。

          液体剂型对于吞咽固体药丸有困难的患者很有用,因为液体药物的吸收速度比固体剂量更快。此外,由于其味道鲜美,非常适合儿童和老年人使用。宝洁、辉瑞、葛兰素史克集团等主要市场参与者提供液体抗酸药来推动细分市场的增长。

           

          抗酸药市场按药物类别细分

           

          先进的药物输送系统和日益增多的胃肠道疾病助长了该领域的主导地位

          根据药物类别,抗酸药市场包括质子泵抑制剂 (PPI)、H2 拮抗剂和酸中和剂,其中质子泵抑制剂部分在 2019 年占据了最大的收入份额。这些抑制剂作用于胃内壁细胞并停止酸的产生。它们主要包括兰索拉唑、埃索美拉唑、泮托拉唑等。它们可预防十二指肠和胃溃疡,还可抑制胃酸反流对下食道造成的损害。抑制剂部分的增长归因于新的药物输送系统、消化性溃疡的流行和其他胃肠道疾病。

          H2 拮抗剂领域在 2019 年占据第二大市场份额,复合年增长率显著。它们也被称为 H2 阻滞剂,可阻碍组胺的作用以抑制胃酸的产生。这些拮抗剂在体内吸收良好,可缓解胃灼热、胃炎、胃部发炎和消化性溃疡等问题。在某些情况下,如果患者在服用质子泵抑制剂时遇到任何副作用,医生会给他们开 H2 拮抗剂。此外,GERD 和应激性溃疡的患病率不断上升,可能会促进节段性增长。

           

          抗酸市场区域洞察

          从地理上看,全球抗酸药市场分为北美洲、欧洲、亚太地区 (APAC)、中东和非洲 (MEA) 以及南美洲和中美洲 (SCAM)。

          2019 年,北美在全球抗酸药市场占据主导地位,预计在整个预测期内仍将保持主导地位。区域抗酸药市场领域分为美国、加拿大和墨西哥,其中美国处于领先地位。由于生活方式的改变导致胃肠道疾病病例增加、政府为缓解胃肠道疾病提供援助、先进的医疗基础设施、不断扩大的制药行业、报销范围以及知名市场参与者的存在,这些都是促进北美抗酸药市场增长的有利因素。

          预计亚太地区抗酸药市场在预测期内将以最高的复合年增长率增长。该地区包括中国、日本、印度、澳大利亚和韩国等主要经济体,其中中国、日本和印度占据了具体的市场份额。亚太地区快速增长的抗酸药市场已习惯于改变生活方式和食品消费模式、扩大制药行业、对非处方药的需求不断增长、抗酸药销售额不断增长以及当地参与者的战略发展。

           

          抗酸药市场报告范围

          报告属性细节
          2019 年市场规模85.5亿美元
          2027 年市场规模116.7亿美元
          全球复合年增长率(2019 - 2027)4.0%
          历史数据2017-2018
          预测期2020-2027
          涵盖的领域按剂型
          • 药片
          • 液体
          • 其他的
          按药物类别
          • 质子泵抑制剂
          • H2 拮抗剂
          • 酸中和剂
          按分销渠道
          • 医院药房
          • 零售药店
          • 网上药店
          覆盖地区和国家北美
          • 我们
          • 加拿大
          • 墨西哥
          欧洲
          • 英国
          • 德国
          • 法国
          • 俄罗斯
          • 意大利
          • 欧洲其他地区
          亚太
          • 中国
          • 印度
          • 日本
          • 澳大利亚
          • 亚太其他地区
          南美洲和中美洲
          • 巴西
          • 阿根廷
          • 南美洲和中美洲其他地区
          中东和非洲
          • 南非
          • 沙特阿拉伯
          • 阿联酋
          • 中东和非洲其他地区
          市场领导者和主要公司简介
          •  
          • 拜耳公司
          • 葛兰素史克公司
          • 武田药品工业株式会社
          • 太阳制药工业有限公司
          • 赛诺菲
          • 勃林格殷格翰国际有限公司
          • 雷迪博士实验室
          • 辉瑞公司
          • 利洁时集团
          • 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。

           

           

          主要市场参与者:

           

          • 拜耳公司(德国)
          • 葛兰素史克公司 (英国)
          • 武田药品工业株式会社 (日本)
          • 太阳制药工业有限公司 (印度)
          • 赛诺菲(法国)
          • 勃林格殷格翰国际有限公司 (德国)
          • 雷迪博士实验室(印度)
          • 辉瑞公司 (美国)
          • 利洁时集团有限公司 (英国)
          • 宝洁(美国)

           

          抗酸剂市场的关键发展:

          • 2018 年 6 月:

            葛兰素史克公司以约 130 亿美元的估值收购了诺华约 36.5% 的股份。此次收购有助于该公司加强其全球消费者保健业务。
          • 2020 年 8 月:

            武田药品工业株式会社宣布,将其在日本运营的全资子公司武田消费者保健有限公司转让给黑石集团。
          • 2017 年 5 月:

            辉瑞有限公司(印度)在印度收购了阿斯利康公司的品牌 Neksium。该交易价值约为 7.5 亿卢比。Neksium 是一种含有埃索美拉唑作为 API 的抗酸药。

           

          报告范围

          全球抗酸药市场研究报告对非处方药的市场规模、份额、趋势和预测进行了详细分析。该报告提供了有关驱动因素、限制因素、机会、细分市场和行业格局的清晰而准确的见解。报告阐述了 COVID-19 的影响以及全球和区域市场观察到的后果。分段分析以各占收入份额和年增长率的主导市场为特色。

          Antacid Market Report Scope

          Report Attribute Details
          Market size in US$ 8.55 Billion
          Market Size by US$ 11.67 Billion
          Global CAGR 4.0%
          Historical Data 2017-2018
          Forecast period 2020-2027
          Segments Covered By 剂型(片剂、液体、其他)
          By 药物类别(质子泵抑制剂、H2 拮抗剂、酸中和剂)
          By 分销渠道(医院药房、零售药房、网上药房)
          By 地理(北美洲、欧洲、亚太地区、中东和非洲、南美洲和中美洲)
          Regions and Countries Covered 北美(美国、加拿大、墨西哥)
          • 北美(美国、加拿大、墨西哥)
          欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
          • 欧洲(英国、德国、法国、俄罗斯、意大利、欧洲其他地区)
          亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
          • 亚太地区(中国、印度、日本、澳大利亚、亚太地区其他地区)
          南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
          • 南美洲和中美洲(巴西、阿根廷、南美洲和中美洲其他地区)
          中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
          • 中东和非洲(南非、沙特阿拉伯、阿联酋、中东和非洲其他地区)
          Market leaders and key company profiles
        • Bayer AG
        • GlaxoSmithKline plc
        • Takeda Pharmaceutical Company Limited
        • Sun Pharmaceutical Industries Ltd
        • Sanofi
        • Boehringer Ingelheim International GmbH
        • Dr Reddys Laboratories
        • Pfizer Inc
        • Reckitt Benckiser Group Plc
        • Report Coverage
          Report Coverage

          Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

          Segment Covered
          Segment Covered

          This text is related
          to segments covered.

          Regional Scope
          Regional Scope

          North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

          Country Scope
          Country Scope

          This text is related
          to country scope.

          Frequently Asked Questions


          Who are the major players in the antacid market?

          The antacid market majorly consists of the players such as Sanofi, GlaxoSmithKline plc, Bayer AG, Takeda Pharmaceutical Company Limited, Sun Pharmaceuticals Ltd, Boehringer Ingelheim International Gmbh, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc, Reckitt Benckiser Group Plc., and Procter And Gamble amongst others.

          What are the driving factors for the antacid market across the globe?

          The factors that are driving growth of the market are increasing prevalence of GERD, and rising prevalence of obesity. However, low awareness associated with gastrointestinal disorders in low-income economies is restricting the market growth.

          What are antacids?

          The class of drugs that neutralize the acid in the stomach are known as antacids. It is used to treat conditions like heartburn, indigestion, acidity and an upset stomach. These drugs are available over the counter and are usually consumed by mouth. They are available in tablets, capsules, liquid and powder form.

          The List of Companies - Antacid Market

          1. Bayer AG
          2. GlaxoSmithKline plc.
          3. Takeda Pharmaceutical Company Limited
          4. Sun Pharmaceutical Industries Ltd
          5. Sanofi
          6. Boehringer Ingelheim International GmbH
          7. Dr. Reddy's Laboratories
          8. Pfizer Inc.
          9. Reckitt Benckiser Group Plc
          10. Procter & Gamble

          The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

          1. Data Collection and Secondary Research:

          As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

          Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

          1. Primary Research:

          The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

          For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

          A typical research interview fulfils the following functions:

          • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
          • Validates and strengthens in-house secondary research findings
          • Develops the analysis team’s expertise and market understanding

          Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

          • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
          • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

          Below is the breakup of our primary respondents by company, designation, and region:

          Research Methodology

          Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

          1. Data Analysis:

          Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

          • Macro-Economic Factor Analysis:

          We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

          • Country Level Data:

          Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

          • Company Profile:

          The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

          • Developing Base Number:

          Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

          1. Data Triangulation and Final Review:

          The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

          We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

          We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

          Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

          Trends and growth analysis reports related to Pharmaceuticals : READ MORE..